B7 homolog 3 (B7-H3), also known as CD276, is a member of the B7 family of immunomodulatory proteins that is overexpressed in a variety of solid tumors and is associated with disease progression, an increased risk of recurrence, decreased survival, and drug resistance, making it a potential target for cancer immunotherapy [73]. Here, CD276 is linked to cancer.